Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBLGNASDAQ:IMVNASDAQ:ONCYNASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBLGFibroBiologics$0.61-1.1%$0.82$0.59▼$5.62$23.42M-0.78301,485 shs338,341 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsONCYOncolytics Biotech$1.01+9.8%$0.56$0.33▼$1.53$86.73M1.07682,959 shs2.63 million shsQNTMQuantum Biopharma$16.56-2.9%$15.11$2.70▼$38.25$49.60M0.67917,702 shs202,350 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBLGFibroBiologics-5.32%-2.76%-36.72%-25.77%-87.73%IMVIMV0.00%0.00%0.00%0.00%0.00%ONCYOncolytics Biotech+12.10%+30.66%+180.56%+106.12%-1.94%QNTMQuantum Biopharma-3.44%-18.22%+7.18%+167.96%+1,655,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFBLGFibroBiologics2.5355 of 5 stars3.62.00.00.00.63.30.6IMVIMVN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech1.6808 of 5 stars3.43.00.00.02.00.00.0QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBLGFibroBiologics 3.20Buy$13.002,048.76% UpsideIMVIMV 0.00N/AN/AN/AONCYOncolytics Biotech 2.75Moderate Buy$4.33329.04% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMV, QNTM, ONCY, and FBLG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025QNTMQuantum BiopharmaSingular ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy6/17/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/21/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/16/2025ONCYOncolytics BiotechJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/15/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBLGFibroBiologicsN/AN/AN/AN/A$0.08 per shareN/AIMVIMV$330K0.00N/AN/A($0.69) per share0.00ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$4.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBLGFibroBiologics-$11.16M-$0.21N/AN/AN/AN/A-1,022.04%-117.56%8/6/2025 (Estimated)IMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/AONCYOncolytics Biotech-$23.14M-$0.29N/AN/AN/AN/A-313.77%-130.19%7/30/2025 (Estimated)QNTMQuantum Biopharma-$14.20M-$15.98N/AN/AN/AN/A-155.20%-94.90%8/13/2025 (Estimated)Latest IMV, QNTM, ONCY, and FBLG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ONCYOncolytics Biotech-$0.09-$0.06+$0.03-$0.06N/AN/A5/14/2025Q1 2025QNTMQuantum Biopharma-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million5/13/2025Q1 2025FBLGFibroBiologics-$0.10-$0.14-$0.04-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFBLGFibroBiologicsN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBLGFibroBiologicsN/A1.141.14IMVIMVN/A2.932.93ONCYOncolytics BiotechN/A3.203.20QNTMQuantum BiopharmaN/A0.960.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBLGFibroBiologicsN/AIMVIMV15.37%ONCYOncolytics Biotech6.82%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipFBLGFibroBiologics20.80%IMVIMV0.33%ONCYOncolytics Biotech0.10%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBLGFibroBiologics1038.26 million30.30 millionN/AIMVIMV9711.71 million11.67 millionOptionableONCYOncolytics Biotech3094.28 million94.19 millionNot OptionableQNTMQuantum BiopharmaN/A2.91 million2.66 millionN/AIMV, QNTM, ONCY, and FBLG HeadlinesRecent News About These CompaniesQNTM - Quantum BioPharma Ltd Ordinary Shares - MorningstarJuly 3, 2025 | morningstar.comMQuantum BioPharma Announces Private Placement - The Manila TimesJune 29, 2025 | manilatimes.netMQuantum BioPharma completes $600 private placement of voting sharesJune 29, 2025 | investing.comQuantum BioPharma Announces Private Placement of 12 Class A Multiple Voting Shares at a Price of $50 Per Share - Yahoo FinanceJune 29, 2025 | finance.yahoo.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering - MorningstarJune 27, 2025 | morningstar.comMQuantum BioPharma Announces Private PlacementJune 27, 2025 | globenewswire.comBest Cannabis Stocks To Watch Today - June 26thJune 26, 2025 | marketbeat.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public OfferingJune 26, 2025 | globenewswire.comCannabis Stocks To Research - June 25thJune 25, 2025 | marketbeat.comTop Cannabis Stocks To Keep An Eye On - June 23rdJune 23, 2025 | marketbeat.comWhat is Singular Research's Estimate for QNTM Q1 Earnings?June 23, 2025 | marketbeat.comQuantum Biopharma (NASDAQ:QNTM) Upgraded at Singular ResearchJune 21, 2025 | marketbeat.comCannabis Stocks To Follow Today - June 20thJune 20, 2025 | marketbeat.comUnbuzzd Wellness Inc Ordinary Shares - Class B (Sub Voting)June 19, 2025 | morningstar.comMQuantum, CyberCatch, Kodiak at 52-Week Highs on NewsJune 18, 2025 | ca.finance.yahoo.comSingular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline ProgressJune 18, 2025 | newsfilecorp.comNKeg, LQWD, Quantum at 52-Week Highs on NewsJune 17, 2025 | baystreet.caCannabis Stocks To Add to Your Watchlist - June 17thJune 17, 2025 | marketbeat.comQuantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General HospitalJune 17, 2025 | globenewswire.comQuantum BioPharma plans special dividend tied to legal actionJune 14, 2025 | investing.comBest Cannabis Stocks To Add to Your Watchlist - June 13thJune 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMV, QNTM, ONCY, and FBLG Company DescriptionsFibroBiologics NASDAQ:FBLG$0.60 -0.01 (-1.14%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.61 +0.01 (+0.99%) As of 07/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.IMV NASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Oncolytics Biotech NASDAQ:ONCY$1.01 +0.09 (+9.79%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.00 -0.01 (-0.99%) As of 07/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Quantum Biopharma NASDAQ:QNTM$16.56 -0.50 (-2.93%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$16.55 -0.01 (-0.09%) As of 07/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
